Squarepoint Ops LLC Tricida, Inc. Transaction History

Squarepoint Ops LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$0.14 - $12.49 $2,852 - $254,471	-20,374 Reduced 52.01%	18,801 $2,000
Q3 2022 Nov 14, 2022	BUY	$8.51 - $13.6 $66,165 - $105,740	7,775 Added 24.76%	39,175 $411,000
Q2 2022 Aug 15, 2022	SELL	$7.31 - $11.85 $445,105 - $721,546	-60,890 Reduced 65.98%	31,400 $304,000
Q1 2022 May 16, 2022	BUY	$7.35 - $10.63 $678,331 - $981,042	92,290 New	92,290 $759,000
Q2 2021 Aug 16, 2021	SELL	$3.95 - $5.41 $154,243 - $211,255	-39,049 Closed	0 $0

Q1 2021 May 17, 2021	BUY	$4.52 - $7.8 $32,543 - $56,160	7,200 Added 22.61%	39,049 $207,000
Q4 2020 Feb 16, 2021	SELL	$4.37 - $9.46 $56,941 - $123,263	-13,030 Reduced 29.03%	31,849 $225,000
Q3 2020 Nov 16, 2020	BUY	$8.56 - $26.93 $384,164 - $1.21 Million	44,879 New	44,879 $407,000
Q1 2020 May 15, 2020	SELL	$18.43 - $38.04 $99,853 - $206,100	-5,418 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$29.6 - $43.71 $160,372 - $236,820	5,418 New	5,418 $204,000

30K

124K

46.5K

Ticker TCDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,668,900
Market Cap $557K
Description
Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company ...

Get notified when there are updates to the investment portfolio of Squarepoint Ops LLC, based on Form 13F filings with the SEC.

Stay updated on Squarepoint Ops LLC with notifications on news.